Skip to main content

Advertisement

Table 1 Patient Characteristics

From: eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial

Variable CT + B (n = 114) n (%) CT (n = 123) n (%)
Median age, years (range) 66 (34–83) 67 (37–82)
Gender
 Male 70 (61.4) 74 (60.2)
 Female 44 (38.6) 49 (39.8)
Performance status (ECOG)
 0 97 (85.1) 102 (82.9)
 1 17 (14.9) 21 (17.1)
Tumor localization
 Rectum 31 (27.2) 34 (27.6)
 Colon 83 (72.8) 89 (72.4)
Histology
 Adenocarcinoma 104 (91.2) 119 (96.8)
 Mucinous adenocarcinoma 10 (8.8) 4 (3.2)
Grade
 1 0 0
 2 56 (64.4) 67 (65.1)
 3 31 (35.6) 36 (34.9)
 Unknown 27 20
Stage at diagnosis
 I–III 29 (26.4) 31 (27.2)
 IV 81 (73.4) 83 (72.8)
 Unknown 4 9
Chemotherapy regimen planned
 FOLFOX4 69 (60.5) 73 (59.4)
 FOLFIRI 45 (39.5) 50 (40.6)
KRAS statusa
 Wild type 67 (59.8) 69 (58.5)
 Mutated 45 (40.2) 49 (41.5)
 Unknown 2 5
Prior cancer therapy
 Surgery 88 (77.2) 91 (74.0)
 Radiotherapy 11 (9.6) 11 (8.9)
 Adjuvant chemotherapy 18 (15.8) 17 (13.8)
  1. aMandatory as consequence of amendment n.1 of 3 May 2009.